RPRX

Royalty Pharma Stock Analysis

AI Rating

Neutral
  • Quality6/10
  • Growth↑ 5/10
  • Value↓ 1/10
Royalty Pharma sales and earnings growth
RPRX Growth
Neutral
  • Revenue Y/Y↑ 7.73%
  • EPS Y/Y↓ -22.67%
  • FCF Y/Y↓ -9.12%
Royalty Pharma gross and profit margin trends
RPRX Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 33.90%
  • ROIC 5Y↓ 4.48%
Royalty Pharma recent dividend growth
RPRX Dividends
  • Dividend yield 1.69%
  • Growth 3Y↑ 5.11%
  • Payout ratio↑ 47%
Royalty Pharma net debt vs free cash flow
RPRX Risk
Great
  • Debt / Equity↓ 0.9
  • Debt / FCF↓ 3.6
  • Interest coverage↓ 3.5

Royalty Pharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks